Deliver transformative innovation

Every day, Novartis is working to reduce the burden of disease for patients and societies around the world. More than 20 000 Novartis employees in research and development deploy cutting-edge technologies to find new ways to cure disease, intervene earlier in chronic illnesses and improve patients’ quality of life.

2021 highlights

9.5 bn

Invested in R&D
comprising approximately 18.5% of our net sales (USD)

3

Breakthrough therapy designations
from the US Food and Drug Administration (FDA)

54

Ongoing Phase III programs
in our development pipeline

21

Approvals
in the US, the EU, Japan and China for new treatments as well as new indications for existing treatments

In this section

Our approach to R&D We tackle the toughest scientific challenges and prioritize projects with the potential to transform the standard of care for patients.

Advancing a strong and diverse pipeline We have one of the strongest clinical development programs in the industry, spanning around 50 diseases. We focus on areas where unmet need remains high.

Advanced technology platforms We are investing in technologies that offer precise new approaches to fighting otherwise intractable diseases.

Innovation for global health We work to reduce the burden of neglected diseases that affect hundreds of millions of patients worldwide.

Putting patients at the center of our clinical trials We integrate the views of patients and caregivers into how we research and develop new medicines, and we strive to include diverse patient populations in our clinical trials.